CJC-1295 (with DAC) | 2mg & 5mg Research Grade Peptide

Product Overview
CJC-1295 (with DAC) | 2mg & 5mg
CJC-1295 (with DAC) is a long-acting synthetic analogue of Growth Hormone Releasing Hormone (GHRH).
While it shares the same core amino acid sequence as “Mod GRF 1-29,” this specific variant is modified with a Drug Affinity Complex (DAC)—specifically, a maleimidopropionic acid group attached to the Lysine residue at the C-terminus.
The “DAC” Mechanism:
This chemical modification allows the peptide to covalently bind to circulating serum albumin after administration. By “hitching a ride” on albumin, the peptide is protected from enzymatic degradation and renal filtration. This extends its biological half-life from minutes to 6–8 days.
Unlike the “No DAC” version (which creates natural pulses), CJC-1295 with DAC is researched for its ability to provide continuous, basal stimulation of the pituitary gland. This results in a sustained elevation of mean GH and IGF-1 levels, making it the primary reagent for research requiring steady-state hormonal output rather than pulsatile signaling.
 
Technical Specifications
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
Chemical Name: DAC:GRF (Drug Affinity Complex Growth Hormone Releasing Factor)
Format: Lyophilised Cake/Powder
Purity: >99% (HPLC Verified)
Half-Life: Extended (approx. 6–8 days)
Solubility: High (Aqueous)
Solvent: Solvent not included (Sold Separately)
Grade: Analytical Research Grade

Variant Breakdown
2mg Vial: Standard research aliquot.
5mg Vial: High-Concentration Vial.

Note: All variants are contained within a 3ml capacity vial.

Quality AssuranceThis compound has undergone rigorous third-party analysis.
HPLC Verified: Independent analysis confirms peptide purity exceeds 99%.
Mass Spectrometry: Confirms the presence of the maleimidopropionic acid (DAC) group.
TFA Removal: Processed via acetate exchange to ensure cellular viability.

Research MechanismIn laboratory settings, CJC-1295 (with DAC) is utilised to investigate:
Sustained IGF-1 Elevation: Studies demonstrating massive increases in total weekly IGF-1 production due to the lack of “troughs” in GH secretion.
Lipolysis via GH Bleed: Researching the effects of constant GH presence on free fatty acid mobilisation (the “GH Bleed” effect).
Pituitary Load: Investigating the long-term effects of continuous GHRH receptor activation on somatotroph desensitisation.

Safety and HandlingWARNING: This product is exclusively for laboratory research and in vitro use.
Research Only: Not intended for human consumption, bodybuilding, or therapeutic use.
Handling: Wear appropriate personal protective equipment (PPE).
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended. 

Scientific References
 Journal of Clinical Endocrinology & Metabolism (2006) – “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” (The definitive study comparing DAC pharmacokinetics vs placebo). View Article

Drug Design, Development and Therapy (2015) – “Growth hormone-releasing hormone (GHRH) and its analogues: a review.” View Article

Bioconjugate Chemistry (2006) – “Synthesis and albumin binding properties of a maleimide-functionalized GHRH analog.” (Detailed chemical analysis of the DAC mechanism). View Article

Neuroendocrinology (2009) – “Pulsatile versus continuous growth hormone secretion: distinct effects on liver and skeletal muscle.” (Contextual research on why sustained release matters). View Article